Transit agency sues Gilead over pricing of hepatitis C drug
Created 12/10/2014 - 17:21
- The Southeastern Pennsylvania Transportation Authority has filed litigation challenging Gilead Sciences' "exorbitant pricing" for the hepatitis C drug Sovaldi, as reported CNBC Wednesday.
- The agency argues that Gilead's price for the therapy of $1000 per day far exceeds the drug's cost in other countries as well as the originally projected price.
- Gilead commented that the company has "just received the complaint and therefore [has] no comment at this time."
- Earlier this year, the US Senate Finance Committee sent a letter to Gilead questioning the drugmaker's rationale for the price.